Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Essential Tremor Overview 6 Therapeutics Development 7 Pipeline Products for Essential Tremor - Overview 7 Essential Tremor - Therapeutics under Development by Companies 8 Essential Tremor - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Essential Tremor - Products under Development by Companies 11 Essential Tremor - Companies Involved in Therapeutics Development 12 Merz GmbH & Co. KGaA 12 Neurocrine Biosciences, Inc. 13 Sage Therapeutics, Inc. 14 Essential Tremor - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 incobotulinumtoxin A - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 NBI-640756 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 SAGE-217 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 sepranolone - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Essential Tremor - Recent Pipeline Updates 33 Essential Tremor - Dormant Projects 41 Essential Tremor - Discontinued Products 42 Essential Tremor - Product Development Milestones 43 Featured News & Press Releases 43 Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting 43 Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline 44 Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor 45 Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49

Merz GmbH & Co. KGaA Neurocrine Biosciences, Inc. Sage Therapeutics, Inc.